Saturday , January 28 2023

The new peanut allergy may report a "sea change" in the treatment of food allergy,


A a great deal of research is the strongest evidence that children and adolescents can control the substance that can cause life-threatening reactions to peanol allergies – experts say that newer allergic drugs.

After treatment with Aimmune Therapeutics, 67 percent of children and adolescents with peanut allergy can take at least two peanut counts, compared to 4 percent of people in the placebo, according to a New England medical journal. However, this improvement has been damaged – almost all of the researchers who have suffered from a drug, pharmaceutical powder preparation, some of the adverse events, and problems with the gastrointestinal, skin or respiratory system or systemic allergic reactions.

For many years, small research has suggested that influencing peanut effects may have an impact on life-threatening effects, but some external experts say that 550 people can systematically study the first treatment approved by the Food and Drug Administration. Most participants from 4 to 17 years were researchers who found the drug to be effective.

"In my opinion, nowadays we do not have any unsatisfactory cure for allergic food, and in a few years we will go to the landscape where we will have two options for our patients," says Corinne Allison Keet, a pediatric allergologist at the Johns Hopkins Medical School, and today, sea ​​change ". "Products that can be marketed in a short time can not be cured, but I think several different approaches are being studied, and in general, the goal is to have a healing therapist."

Aimmune, which is funding the research, plans to apply to federal regulators next month and suggests it can be launched at the end of 2019. Patients need to know how much time they need, how much time they need and how much it costs.

Director of the Center for Nutrition Allergy at the Massachusetts General Hospital, Wayne G. One of the authors of the study, Schreffler and Aimmune, who received experimental funding and fees, said: "At present, this is a consultation to continue treatment." "Some years later, it would be necessary to conduct additional studies to determine whether some people might change the dose. Many of the researchers have shown patience in treating them and, in my opinion, are telling the truth about using it in the real world if approved. "

Treatment is not a cure, but may not be appropriate for all people with allergic reactions. Patients came to the clinic every two weeks and gradually increased the dose for six months. They got drugs everyday.

"It's important to remember what the purpose of this treatment is, because people can not feed peanuts," says Chief Admiral of Aimmune Daniel Adelman. "Children go out everyday in the morning, parents worry that they will be peanuts and endanger life-threatening. The purpose of this treatment is to help protect people from possible reactions that can endanger life.

Immunity enhances the approach to other nutritional allergies and checks to see if the same drug can work in the next year to eliminate the sensitivity of the child to an allergy to the egg.

Experts warned that such discipline should not be initiated at home.

There are about 6 million children in the United States with food allergies. At the same time, Michael R., a research fellow at the People's Health Research Institute in San Jorge, University of London, Perkin has noted that the potential market for therapy is billions of dollars. The Aimmune Preparation was a defattered flour made by strict production processes requiring pharmaceutical products, which, according to Adelmann, could be a risk that it could lead to an inaccurate dose.

Keita says that parents and children understand the medicines.

"We urge patients to look at labels and do not drink anything with peanuts," Keita said. "We do not know what people will do with this part-protection, which can make people feel false security."

The universal fund was closed on Monday by 11%.

Read more:

FDA approves the first general version of EpiPen

EpiPen developer Mylan has become a virtual monopoly

"Fast release" Tlenolol breaks down slower than dissolving tablet on cheaper tablets

Source link